HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Aims For 'Appropriate Balance' For Resuming Inspections Suspended By Pandemic

Executive Summary

Phased approach will prioritize the safety of FDA and industry employees while striking ‘an appropriate balance between a scaled-back surveillance inspection program and the continuation of providing robust regulatory oversight,’ Commissioner Hahn says in a memo from self-isolation.

You may also be interested in...



US FDA Suspends Domestic Inspections As Staff Work Remotely In Covid-19 Response

Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the virus, and breakthrough products such as cancer treatments.

Defense Secretary Asked To Brief US Congress On Pharmaceutical Supply Chain Security

Congress seeks advice from Defense Department on procuring active pharmaceutical ingredients domestically for national security purposes as efforts to identify areas of concern get underway.

The Quality Lowdown: Pandemic Site Evaluation Creativity On Display As COVID Clampdown Returns

With a virtual visit to SciVac in Israel, a belated Revance site inspection in California and two weeks at a Dr. Reddy’s site in India, the US FDA finds ways to overcome travel restrictions in its efforts to oversee drug manufacturing quality.

Topics

UsernamePublicRestriction

Register

RS150030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel